enGene Therapeutics Inc. (ENGN)
ENGN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ENGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001980845 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Canada |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Liquidity and Going Concern In accordance with Accounting Standards Codification ( ASC ) 205-40, Going Concern, the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued." | 10-Q 2026-09-08 |
| Cash and burn | $41.0M cash; operating cash flow -$25.8M a quarter. | Report 2026-07-31 |
| Shares outstanding | 67,016,316 (2026-09-02); 51,191,771 a year earlier. | Cover page 2026-09-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-03-09 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Montreal, Canada | PCAOB Form AP 2026-01-19 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $10K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-07-31 | Not filed | -$32.5M | -$18.9M | $41.0M | $199K | Needs four quarters | 10-Q 2026-09-08 |
| Q2 2026 2026-04-30 | Not filed | -$30.2M | -$30.5M | $29.8M | $193K | Needs four quarters | 10-Q 2026-09-08 |
| Q1 2026 2026-01-31 | Not filed | -$29.8M | -$28.9M | $36.6M | $188K | Needs four quarters | 10-Q 2026-09-08 |
| Q4 2025 2025-10-31 | Not filed | -$37.9M | -$25.0M | $50.2M | $8.0M | Needs four quarters | 10-K 2025-12-22 |
| Q3 2025 2025-07-31 | Not filed | -$29.0M | -$25.6M | $32.6M | $5.4M | Needs four quarters | 10-Q 2026-09-08 |
| Q2 2025 2025-04-30 | Not filed | -$25.8M | -$22.9M | $57.5M | $3.6M | Needs four quarters | 10-Q 2026-09-08 |
| Q1 2025 2025-01-31 | Not filed | -$24.6M | -$25.7M | $62.3M | $1.7M | Needs four quarters | 10-Q 2026-09-08 |
| Q4 2024 2024-10-31 | Not filed | -$15.3M | -$19.6M | $173.0M | $699K | Needs four quarters | 10-K 2025-12-22 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-09 |
| Latest annual report | 10-K/A | 2026-02-19 |
| Latest quarterly / interim | 10-Q | 2026-09-08 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-05-08 |
Source: SEC EDGAR submissions feed, 272 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +37.7% |
| 1 month | +47.9% |
| 3 months | +42.6% |
| Year to date | -73.3% |
| 1 year | -71.4% |
| From 52-week high | -80.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| ENGNW | enGene Therapeutics Inc. Warrants | $0.2100 |
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CRDL | Cardiol Therapeutics Inc. Class A Common Shares | $0.9798 | -2.02% | $125.1M |
| LENZ | LENZ Therapeutics Inc. | $3.82 | -7.51% | $120.0M |
| CMPX | Compass Therapeutics Inc. | $0.6615 | -14.51% | $119.1M |
| FATE | Fate Therapeutics Inc. | $1.14 | -10.94% | $138.6M |
| ARMP | Armata Pharmaceuticals Inc. | $2.99 | -22.74% | $111.2M |
| TARA | Protara Therapeutics Inc. | $2.38 | -5.93% | $146.5M |
| HUMA | Humacyte Inc. | $0.5403 | -3.24% | $150.1M |
| ZURA | Zura Bio Limited | $1.08 | -12.90% | $104.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier